PATENT CLAIM ANALYSIS

Application Number: 15946578
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-02
Patent Classification: ["514", "312000"]

Abstract:
The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics.

Claim (Index 58):
The method of  claim 54 , wherein the FTI is administered at a dose of 300 mg twice a day.

Metadata:
- Claim Count in Document: 101.0
- Percentile: 91.0
- Lexical Diversity: 1.2766
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15820157', '15820012', '15844478', '15238458', '15905711']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7881599708720303
- 35 USC 102 Novelty (BERT): 0.6506576865678818
- Combined Prediction Score: 0.7744097424416154
- Mean Citation Score: 468.511828
- Max Citation Score: 668.1744
- Similarity Product: 564.5083391140938

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test